The German company's product candidates are being developed in the field of immuno-oncology and in total it has six assets in its pipeline.

In August 2018, Affimed signed a deal with Roche's Genentech unit that is worth $96 million up front, but with milestone payments and royalties could total up to $5 billion. The companies will develop and market novel NK cell engager-based drugs to treat several cancers.